Crescent Biopharma Inc 宣布，其两款在研新药——PD-1/VEGF双特异性抗体CR-001，以及靶向整合素β6（ITGB6）的抗体偶联药物（ADC）CR-003——的新药临床试验（IND）申请已获得监管机构批准。这两款候选药物均拟用于实体瘤的治疗，标志着公司在肿瘤免疫治疗领域取得重要进展。
Crescent Biopharma Inc 宣布，其两款在研新药——PD-1/VEGF双特异性抗体CR-001，以及靶向整合素β6（ITGB6）的抗体偶联药物（ADC）CR-003——的新药临床试验（IND）申请已获得监管机构批准。这两款候选药物均拟用于实体瘤的治疗，标志着公司在肿瘤免疫治疗领域取得重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.